SCHEMBL2222167

SCHEMBL2222167

CC1(C)CCC(C)(C)c2cc(-c3csc(N4CCC(N5CCN(CCO)CC5)CC4)n3)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 3/20 0.42
CTSS P25774 3/20 0.42
CTSL P07711 2/20 0.42
SMN1; SMN2 Q16637 12/20 0.41
RAB9A P51151 9/20 0.41
NPC1 O15118 7/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
CDC25A P30304 1/20 0.41
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2225854 0.96 PTPN1 (0.41) CTSBCTSSCTSLSMN1; SMN2RAB9A
SCHEMBL2222158 0.90 PTPN1 (0.46) CTSBCTSSCTSLSMN1; SMN2RAB9A
SCHEMBL2225727 0.90 CTSB (0.41) CTSBCTSSCTSLSMN1; SMN2RAB9A
SCHEMBL2224786 0.88 PTPN1 (0.44) CTSBCTSSCTSLSMN1; SMN2RAB9A
SCHEMBL2225002 0.84 PTPN1 (0.44) CTSBCTSSCTSLSMN1; SMN2RAB9A
SCHEMBL12632972 0.84 RARB (0.43) ALDH1A1LMNAL3MBTL1ENPP2
SCHEMBL2224704 0.84 AR (0.51) CTSBCTSSCTSLSMN1; SMN2RAB9A
SCHEMBL12517116 0.84 PTPN1 (0.44) CTSBCTSSCTSLSMN1; SMN2RAB9A
SCHEMBL12517375 0.84 PTPN1 (0.44) CTSBCTSSCTSLSMN1; SMN2RAB9A
SCHEMBL12515992 0.83 PTPN1 (0.43) CTSBCTSSCTSLSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907098-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-8907098-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-8907098-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
EP-2513066-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252815-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252815-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252815-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011082732-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-07-14 WO disclosed
WO-2011082732-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252815-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, S1PR3, SPHK2 CTSB 2808/4885CTSS 1986/4885CTSL 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.